0001213900-23-033507.txt : 20230428 0001213900-23-033507.hdr.sgml : 20230428 20230428081036 ACCESSION NUMBER: 0001213900-23-033507 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20230428 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230428 DATE AS OF CHANGE: 20230428 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Protara Therapeutics, Inc. CENTRAL INDEX KEY: 0001359931 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 204580525 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36694 FILM NUMBER: 23860352 BUSINESS ADDRESS: STREET 1: 345 PARK AVENUE SOUTH STREET 2: 3RD FLOOR CITY: NEW YORK STATE: NY ZIP: 10010 BUSINESS PHONE: 646-844-0337 MAIL ADDRESS: STREET 1: 345 PARK AVENUE SOUTH STREET 2: 3RD FLOOR CITY: NEW YORK STATE: NY ZIP: 10010 FORMER COMPANY: FORMER CONFORMED NAME: ArTara Therapeutics, Inc. DATE OF NAME CHANGE: 20200110 FORMER COMPANY: FORMER CONFORMED NAME: PROTEON THERAPEUTICS INC DATE OF NAME CHANGE: 20060420 8-K 1 ea177564-8k_protara.htm CURRENT REPORT
0001359931 false 0001359931 2023-04-28 2023-04-28 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): April 28, 2023

 

Protara Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware   001-36694   20-4580525
(State or other jurisdiction
of incorporation)
  (Commission File No.)   (IRS Employer
Identification No.)

 

345 Park Avenue South

Third Floor

New York, NY

  10010
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (646) 844-0337

 

N/A

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.001 per share   TARA   The Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

Item 7.01. Regulation FD Disclosure.

 

On April 28, 2023, Protara Therapeutics, Inc. issued a press release entitled “Protara Therapeutics Announces Positive Preliminary Data from ADVANCED-1 Phase 1a Dose Escalation Trial of TARA-002 in NMIBC Supporting Advancement into Phase 2 Clinical Development,” a copy of which is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K.

 

The information in this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

 

1

 

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No.   Description
     
99.1   Press Release dated April 28, 2023, issued by the Registrant.
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

2

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  PROTARA THERAPEUTICS, INC.
     
Date: April 28, 2023 By: /s/ Patrick Fabbio
    Patrick Fabbio
    Chief Financial Officer

 

 

3

 

 

EX-99.1 2 ea177564ex99-1_protara.htm PRESS RELEASE DATED APRIL 28, 2023, ISSUED BY THE REGISTRANT

Exhibit 99.1

 

Protara Therapeutics Announces Positive Preliminary Data from ADVANCED-1 Phase 1a
Dose Escalation Trial of TARA-002 in NMIBC Supporting Advancement into Phase 2
Clinical Development

 

Favorable tolerability observed in patients with NMIBC treated with TARA-002 in ADVANCED-1 trial

 

·Anti-tumor activity was observed in all three evaluable patients with CIS, including one heavily pre-treated BCG-unresponsive patient who achieved a complete response

 

·       Company’s current resources are expected to fund operations into 2025 supporting the initiation of the ADVANCED-2 trial in BCG-naïve CIS patients and BCG-unresponsive CIS patients in 2H’2023

 

New York, April 28, 2023 -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced positive preliminary results from the Phase 1a dose-escalation component of its ongoing ADVANCED-1 clinical trial of TARA-002, the Company’s investigational cell-based therapy, for the treatment of patients with high-grade non-muscle invasive bladder cancer (NMIBC). The clinical data indicate that TARA-002, a novel intravesical monotherapy, was generally well tolerated and showed anti-tumor activity in high-grade NMIBC patients. The data will be featured during a moderated poster session at the American Urological Association (AUA) 2023 Annual Meeting being held in Chicago from April 28, 2023 to May 1, 2023.

 

“These promising results suggest TARA-002 may provide meaningful benefit to patients with NMIBC, who currently have limited treatment options,” said Neal Shore, M.D., Medical Director, Carolina Urologic Research Center, Chief Medical Officer, GenesisCare US, and study investigator. “These data show favorable tolerability and initial evidence of anti-tumor activity, thus serving as an impetus to advance TARA-002 into larger, later-stage trials.”

 

“We are highly encouraged by preliminary results from the dose-escalation component of ADVANCED-1 and look forward to deepening our understanding of TARA-002’s potential in the ongoing expansion trial, which is currently enrolling NMIBC patients with carcinoma in situ (CIS),” said Jathin Bandari, M.D., Chief Medical Officer of Protara Therapeutics. “We plan to initiate larger clinical trials in NMIBC patients with CIS who are Bacillus Calmette-Guérin (BCG)-naïve and BCG-unresponsive in the second half of this year.”

 

Preliminary Results

 

TARA-002 was generally well tolerated at all three dose levels evaluated in the trial, and no dose limiting toxicities were observed. A maximum tolerated dose was not determined, and dose escalation remains ongoing in exploratory cohorts. The Company has selected the 40KE1 dose for use in subsequent clinical trials.
   
The majority of reported adverse events were Grades 1 and 2 across all dose levels, and treatment-related adverse events, as assessed by study investigators, were in line with typical responses to bacterial immunopotentiation, and included fatigue, headache, fever, and chills. The most common urinary symptoms were urinary urgency, urinary frequency, urinary tract pain/burning, incomplete emptying, and bladder spasm. Most bladder irritations resolved soon after administration or in a few hours to a few days.
   
A total of nine patients were enrolled in the study, including three patients with CIS who reached the three-month efficacy assessment. Of those three patients with CIS, one heavily pre-treated BCG-unresponsive patient achieved a complete response (CR) at the 20KE dose, and tumor regression was observed in the other two patients.

 

 

 

A copy of the AUA poster will be available in the Events and Presentations section of the Company’s website: https://ir.protaratx.com. The Company plans to present complete results from the ADVANCED-1 study at a subsequent medical conference.

 

Patient enrollment is ongoing in the open-label expansion trial (ADVANCED-1EXP), which is evaluating intravesical TARA-002 at the 40KE dose in 12 CIS patients, including BCG-naïve, BCG-unresponsive, and BCG-inadequately treated patients.

 

Clinical Development Plan Update

 

Based on these results, Protara is advancing the clinical development of TARA-002 for the treatment of NMIBC. The Company plans to initiate ADVANCED-2, a Phase 1b/2 open-label trial evaluating intravesical TARA-002 in up to 102 patients with CIS. The Phase 1b trial is expected to enroll 27 patients with CIS (± Ta/T1), BCG-Naïve or BCG-experienced, who have not received intravesical BCG for at least 24 months prior to CIS diagnosis. The Phase 2 trial is expected to enroll 75 patients with BCG-unresponsive CIS (± Ta/T1). ADVANCED-2 is expected to initiate in the second half of 2023.

 

About ADVANCED-1

 

ADVANCED-1 is a Phase 1 dose-finding, open-label trial (NCT05085977) evaluating TARA-002 in treatment-naïve and treatment-experienced NMIBC patients with carcinoma in situ (CIS) and high-grade papillary tumors (Ta). In the initial dose escalation phase of the trial, patients received six weekly intravesical doses of TARA-002 evaluating the 10KE, 20KE and 40KE doses. The primary objective of the trial was to evaluate the safety, tolerability and preliminary signs of anti-tumor activity of TARA-002, with the goal of establishing a recommended dose for a future Phase 2 clinical trial.

 

About TARA-002

 

TARA-002 is an investigational cell therapy in development for the treatment of NMIBC and of LMs for which it has been granted Rare Pediatric Disease Designation by the U.S. Food and Drug Administration. TARA-002 was developed from the same master cell bank of genetically distinct group A Streptococcus pyogenes as OK-432, a broad immunopotentiator marketed as Picibanil® in Japan and approved in Taiwan by Chugai Pharmaceutical Co., Ltd. Protara has successfully shown manufacturing comparability between TARA-002 and OK-432.

 

When TARA-002 is administered, it is hypothesized that innate and adaptive immune cells within the cyst or tumor are activated and produce a strong immune cascade. Neutrophils, monocytes and lymphocytes infiltrate the abnormal cells and various cytokines, including interleukins IL-2, IL-6, IL-8, IL-10, IL-12, interferon (IFN)-gamma, and tumor necrosis factor (TNF)-alpha are secreted by immune cells to induce a strong inflammatory reaction and destroy the abnormal cells.

 

About Non-Muscle Invasive Bladder Cancer

 

Bladder cancer is the 6th most common cancer in the United States, with NMIBC representing approximately 80% of bladder cancer diagnoses. Approximately 65,000 patients are diagnosed with NMIBC in the United States each year. NMIBC is cancer found in the tissue that lines the inner surface of the bladder that has not spread into the bladder muscle.

 

2

 

 

About Protara Therapeutics, Inc.

 

Protara is committed to advancing transformative therapies for people with cancer and rare diseases. Protara’s portfolio includes its lead program, TARA-002, an investigational cell-based therapy being developed for the treatment of non-muscle invasive bladder cancer and lymphatic malformations, and IV Choline Chloride, an investigational phospholipid substrate replacement for patients dependent on parenteral nutrition. For more information, visit www.protaratx.com.

 

Reference:

 

1. Klinische Einheit, or KE, is a German term indicating a specified number of dried cells in a vial.

 

Forward-Looking Statements


Statements contained in this press release regarding matters that are not historical facts are “forward looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Protara may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “designed,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words or expressions referencing future events, conditions or circumstances that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such forward-looking statements include but are not limited to, statements regarding Protara’s intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, Protara’s business strategy, including its development plans for its product candidates and plans regarding the timing or outcome of existing or future non-clinical studies and clinical trials, and statements regarding the anticipated safety or efficacy of Protara’s product candidates. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that contribute to the uncertain nature of the forward-looking statements include: risks and uncertainties associated with: Protara’s development programs, including the initiation and completion of non-clinical studies and clinical trials and the timing of required filings with the FDA and other regulatory agencies; general market conditions; changes in the competitive landscape; changes in Protara’s strategic and commercial plans; Protara’s ability to obtain sufficient financing to fund its strategic plans and commercialization efforts; having to use cash in ways or on timing other than expected; the impact of market volatility on cash reserves; and the risks and uncertainties associated with Protara’s business and financial condition in general, including the risks and uncertainties described more fully under the caption “Risk Factors” and elsewhere in Protara’s filings and reports with the United States Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. Protara undertakes no obligation to update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise, except as required by law.

 

Company Contact:

 

Justine O’Malley

Protara Therapeutics

Justine.OMalley@protaratx.com

646-817-2836

 

 

3

 

 

EX-101.LAB 3 tara-20230428_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 4 tara-20230428_pre.xml XBRL PRESENTATION FILE EX-101.SCH 5 tara-20230428.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink XML 6 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Cover
Apr. 28, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Apr. 28, 2023
Entity File Number 001-36694
Entity Registrant Name Protara Therapeutics, Inc.
Entity Central Index Key 0001359931
Entity Tax Identification Number 20-4580525
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 345 Park Avenue South
Entity Address, Address Line Two Third Floor
Entity Address, City or Town New York
Entity Address, State or Province NY
Entity Address, Postal Zip Code 10010
City Area Code 646
Local Phone Number 844-0337
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.001 per share
Trading Symbol TARA
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 7 ea177564-8k_protara_htm.xml IDEA: XBRL DOCUMENT 0001359931 2023-04-28 2023-04-28 iso4217:USD shares iso4217:USD shares 0001359931 false 8-K 2023-04-28 Protara Therapeutics, Inc. DE 001-36694 20-4580525 345 Park Avenue South Third Floor New York NY 10010 646 844-0337 false false false false Common Stock, par value $0.001 per share TARA NASDAQ false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://protaratx.com/role/Cover Cover Cover 1 false false All Reports Book All Reports ea177564-8k_protara.htm ea177564ex99-1_protara.htm tara-20230428.xsd tara-20230428_lab.xml tara-20230428_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "ea177564-8k_protara.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "contextCount": 1, "dts": { "inline": { "local": [ "ea177564-8k_protara.htm" ] }, "labelLink": { "local": [ "tara-20230428_lab.xml" ] }, "presentationLink": { "local": [ "tara-20230428_pre.xml" ] }, "schema": { "local": [ "tara-20230428.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2023": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "TARA", "nsuri": "http://protaratx.com/20230428", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "ea177564-8k_protara.htm", "contextRef": "From2023-04-28to2023-04-28", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://protaratx.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "ea177564-8k_protara.htm", "contextRef": "From2023-04-28to2023-04-28", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://protaratx.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://protaratx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://protaratx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://protaratx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://protaratx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://protaratx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://protaratx.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://protaratx.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://protaratx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://protaratx.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://protaratx.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://protaratx.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://protaratx.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://protaratx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://protaratx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://protaratx.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://protaratx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://protaratx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://protaratx.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://protaratx.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://protaratx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://protaratx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://protaratx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://protaratx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://protaratx.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://protaratx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://protaratx.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://protaratx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://protaratx.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://protaratx.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://protaratx.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://protaratx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://protaratx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://protaratx.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://protaratx.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://protaratx.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://protaratx.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://protaratx.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://protaratx.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://protaratx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://protaratx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://protaratx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://protaratx.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://protaratx.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://protaratx.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://protaratx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://protaratx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://protaratx.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://protaratx.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://protaratx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://protaratx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://protaratx.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://protaratx.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://protaratx.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://protaratx.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://protaratx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://protaratx.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://protaratx.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 14 0001213900-23-033507-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-23-033507-xbrl.zip M4$L#!!0 ( %%!G%9>!2&:5!( ,%L 7 96$Q-S]NUSTM-PL8$$2,IS")>$)B$$2)/MEQS9 M%D&)L5W9YI)?_XYD&S#8N95PF M+16+Q?2$PR0\H-(D$D[.9*3TU>E)5QV0(4Y2PW:PH9)9)YT:=_'X>>L,5&$Z M#8'R)P&1;'H%-;1J\PZ+P#MIKS$$ZD2"YCU0)P"EMIF3I=V'^/ @9ATF<; 2 MYQE&2*X..B=S<"<:?@Z:=A@V[+[)AM@!'7),^61&3LH["TB2-E%#B.![ZL8< M/8JGD,Q* 9X5Y81'RIL5;,\DKI$E<0,5,G=B2T: F!JZ9K.&P:S;'?&.I@,V<5-3P, ?4JGU )QJ]ZWKPF'3)RT9X1IWB_MH]W_3S*)&I3H6@EUB;.'6GA( M2FBB3?90LR9^N,[(U>N+[B>Y=EBIM.&#LX>2R:?VSNY>\[%>A\9X'8SQ&8AR MU5FOEW3/UZ\)S"\8 /RM&R#":15DP[#>-#0R.2;3ZPSXH&R^6,Q*S\%;7,!; M&1)#@_^=AHYOKOM8M\DS4.T<@*!KU]*U[QH\G/#H.3CDZ^X ,V)?R]?"$WI( M;/'L.7AJG)>VCRN[PE(L' -(B8]0QA]C8 M]AYL P.,]L5,U^@HZ*=1V]+QM(0,TR"BD4Y*?,H2QFU!?*.:1@QA&?PK +;< M(>!2O4D_<3K<=S28.>1S)9G))>6"8\Y_3B #1@VD""U%SH9$>3X=]M,A$NNA M&IHKB;*8+)&$TJ'AWN61@+JF) MK27\9@<\Q->$38>63CROX),*(_?(V:;+ FH )G1?\H>,J/;@D /O%70C0MJS MI[/G5.,M?4H8$D,ADMM(-5!G3*6A99BO$0/#0%VE8SJY!/2&#V:U(5]A$-@QV4+S\V6PS&,4U@6B M-6*80VH\1O9QN2S3C4(DL")0WT(7[-%S#X%OW$]#?_CD_^U;S_7#>VB( MV0TU2HB#9A(0:E@"V>*2T7%UDFSC&[&R+7IMKV_2,2W1/T"65$S',8?^LS'5 MG 'G)?,I$>JMF R&X/4^T+%ZAV3@P39UJNTA/H"D3>]AF9(X%A\XP.S!2P%\ MHOS?OZ2=S)XG#/_?A1&D0T-8DZ@"DM8O(GQ$?MP])+%.;X"R"JZ-,!"C4KYH M-7OU&NKV*KUZ%^:$4GXO3KKUZD6GV6L"&Y56#=6OJD>5UF$=5<].3YO=;O.L M]:[L75:Z1\W68>^LM8UJJ6H*R9E\KOB>' 43Y_TX:)QU3M&^;6%#N&@>_Q4S M%1'6)I,U4W5YE,(SBFMU%H'/8_%[4ZW3'=#26 -VOAD6+]!+E0O)X.2;: M3W-.R_]LE8&-=>JM'NK4VV>=WKM:5-MEMHL-!SDFH%-YB0!)660R).6WM,_O MR9K91\Z <*Y<1AT*9.H3=8 - Q25745QR%6T1VM:]P#?:9QR,.@>ZDM^5I=R+?897 MD?J:H!.GI &E(?0;:'@Z!=:)$>530HPERA6+41W)A6W$T7XT/_.^ 46[OY34L"U%T$^6V5U1"O0'$\19Q':K"\)N& MFOIHV@21;M4G&+P.'Q,W,#8;"\(VLBVB\OQ50Q3$[MB;&^"HP.#8FARH'Z<^ M::HY6-$)-.HZR$P5]?Y,0GRWL*8%WY_-R$+H/XO@55/7L65#7!_\Y*6%^TZ0 M&>T[VE**$,A:\:+^5'Z>)XP(@RF ]6" H*<9W:S\*48U8JHO#"?9QT.J3TN/ M#6@Q*X'Q1]I-(V0W,#--!HY4%-*[#GBAJE= KII:C!FYG7SAK-V3FU=D'9Z2 MU_MY(<,A%C-'?"Z&7>43^$R4:T3'8W"R#QJ9_Z.CK2IR64V>1F>:DC_-IV14 M]]]Q'N1"\Z!!=0)"4PB+5KKRL\O:-^W>T;=UA-3+-'D!34IF=W:*N7\U^&0- M9D,:[.%)TZ\YJL)*'E)GI=?XNW6LC"ZKA;6I,X:!1%G.)'/Y0B8OYY^H7/B' MQ3O=2$6\NO"WA-/A280)$3Q#MQ# VQH5V<6^PD2]&M90NNBG/K]PUCX\5=]I M_%5S.*0VWWM'W'!1RTS]4>-K=KJH/K1TLLOVZ%AJ@GRK!829G?.8[TA\4+ M+A:#*4HMK",R(:KKT!&OPT"X0>P_*K0"Y2&NO3<)GMZDLOT8K7E9\+]_%61I M=\\&2)U8 ],@R!!YT3;/%7271V^;&Y@1#(:B@=BVXB(6[JLK !=OA9U)(W/> M=B].Y/X:K'"17J*\D]N)L;K/*PM#4%HX,6&NM?F8'\I%9:66.SNJ4_OG.D*K M99J)T5?619E\K77D;0EL-DX$P_0HR$V4]^(H]%PQ_[$XC!O71M2O^D*E>J P%+.=_&P93$3?#BO M"RCF!"E$-\=\S+R12P85DL>H3W4P<41ML'>'&!K1-C<<$^0Q='4'&\1T;7V* M;,@P[?Y4=/5[F HPXB6>_K;A0H'>!40@:&,:M/4A6S/'O!\OHU*>I]NEUQ/N MZV>DL[3S@<4KL;K$!?%9SIJL=1F+28$N&75 J[PXXAI^G<".\<[3UO=JYOS4 MRJQGAU$Q39U@0QS37/2 D2QQ!19W<[F]V-#I@5 CPBS6*5N?81#"(L?(6MC& MY^>C4$[.^_-^:0^=;YUO2;NHVN@@D'8* #__@36:CVT1>=\BNI#>J* 7X^84 M'"-X1SW:',9DVC*:/ZX&9"W;2+'FL,K/1[:%.;KX]L',!U4EU@^]$50\II27E+^?PT4_%@_S66MS:66K2Q-&W;)>Q1 MDSD>W-W(YN'EV=7+3_6\P&16N/NS#"=+DKDM]6F&X\.^O>'\.L*%(-)+K@B# M7-6*.D J_(B?;($(?NO*J6^] MH#*]N.?[ZT+YN'.HY9^C%%.(!.X2? >P#$_F#N:A?8IXL_NK6JW7&XT(PWN/ MLG[,:5S?H4XE61$F%;UFG^0F':5Y>5\YN%U#R7>99J+,%VJ0>]J*O03LA M@HDROWJ_#K&+B/6#R;P'H4'&?<;LE56Q1!^OH%+,[XOQV(5]DC3]1;AH:#X8)4J9(%07^ M(3^#,QX0<=@O7'S?W* V B5#*,TQWR#PTV-GP(-JBU?DL8TTTJ>&=W3>*UUF M\FCU[L_\RD\6;?&![NZ)\F4 #&1 ,18_<\]W5[S(7%:2LH]K<^.1BT0SK#Q, MGW=R-KNQS#<"8B XY&!B388J,S+6) M@ *Z8CL-B;>\PX.H0Q/0IISZF0)L;I@%#@A9&1M2&?F"BV%!YA16K MXK4Y8BN>OXM)PTRSO8TT+2X?S&[A63ZX:'LI--/E1U7:.U^CEZSG7:.?7;O_ MK:_1/RA[SO,>P/]T>8D&T'H#$"'-JBR7WC*PF!TMZDJ2(Y2U(X)#*ZQ;P5O" M/PWGO:]AA30C^"ZI$# MX,\2_"X2VXF@Q1F()3:7:XCDHCH_O":5Z?R=*9 ML;D1ONBZC>*O32+*"ZT:PN".^;$Y!JL!AA5 O$1'AP9^P$K.[$5A0!7# 94 M8F]NM$V^1(P(D"(ZY>\Z85-4PPY&?5C74:7VO=*JUFM)";4''+^$4@"K4 M0<5B2N*KD8CEJBYCG)I_89K//__PR?JBNW4H_@/.Q5#N%PO5XZ$V-68O'.1Z M%Y*?6?_"8;Z0CK9YG4'71>BB$$@+8%[,IFR?POP-],]#%H@S+)ASXFSH+,XH MK"8.FQO1P3Z'\G$O O@D/L\N+XTA_$&VJ]P"#6\6$:13K%#=2R4$00QKBL?# M-K#/_('0A7%PF02WG6!4$,O-WM3%)<0C+O\H4^RIC2#[,5?W&+9Y"8U8XBXR MF0CCY^>DB,-%!0$=D/.O**N;&R'"M@OV@WW:?@3]1UN"=Y1[<95Y(+20]]"9 M);9]2AQ],,_>*-YXV5D\KU3SI,ONB7+X;8+>L/<0?WM+"548S'(U>,$@%TW+ MY$.70G%'T$L$PG]V3/0Z)U/GH5%1A$:-6:8EKF?PA8]74+3 5]KKC9%>P<"V MM,\S9O\I.W]/.R3PA!V;@/RG-6^X!"MMRTP]NBD5,/'K^T\>HD)QW:.I$5ME M5+CFIVP0/:R=R$$^^O")=*)6-G:C;,F9W+:<+6S+^?SG15[6)R8>4T6J.7IH M:]0/1M[K2PF6=G?S.SDR*1:34O 2X=3 &8IC%I"A=/P,11-1T7*FXZWY/!&8P?HG.HW1QN;1!OT8Y2)G:_\BU*<#B3=-G !#:9X&Q<\@'R\'ZPC(L'V 7BUR.6%)X$.N\[ 9.!)M5?< MZON=XM;H\ ^0\57A:T)>Z[G+SAFO%:+>4;U3:=LUJ=QLU6]74X]>47S6" MBS_LN[/>*)V_U["$EM]K^'BZKQZ4#F6YR.?=:ZUEKT#F MQ6%;]M4'][[;W(O^([S1_0X;V4_4?YK_MI2R^(4\SE O/_%WLQ0.KL5I#''K M>.%WNI!OD\;M]\SQ^+9R/JBGS\^FD[SN6(<=2-8:@\L)'9QWKG)MKW?8V9DJW=MA_:CNW+4.^IE; MHWO?4VO]H^,T/M.50XT4VKW3N_N=;_JWP],O%XU[QJZ^VW;=O#T\O[_3IH.C M^D7WFW':^O(M=^P:/^J69AXU\'=\<%HY)\/![<7.!!>^Y# E/XX'7[3O%\:/ MX]&W;P?5HXONE_3Y!9X,:EE-^KN=^T&/3BX&]5/WQJ@/?^K.Z/;2T;[W:K9] M@K7B'4E?IL>5SL5M]^+TJR>2_P=02P,$% @ 44&<5GV$ND&6% ZT\ M !H !E83$W-S4V-&5X.3DM,5]PU<:W/;-I?^KAG]![S9 M>3/QC"1?TESM9E:^)'7K.![;:;R18+ P<&Y/.="'WQW_?[L3;=S\-W)\!@_!?T[N#Z]/CMY<[#M?^+N=KA] MOY"3UPIJ\>/\" > MO?B]S^V+5-J)SEX+&KJS+PIU6_1EHB>X9/5D6CQZZ$*]>#78/ MM@]!]L5#+!BIK%"65WR7P_[.SI[0F3A_?WIX)*[*/#>VT-E$#..9Q,(I M",3]PH19]_ROC )33NL#.%W.>ST\/#L11R=G9Q?# MX^/3\W??/MIYQ-^O+H9'U?>?3H^OO_OVT>[.SK\?_5%"^H7)F9CZPL@4A4GY M&LB[OJQFGBDP#=RHCA4/DBX<7!]7(^8Z+J9X<+#W3&>/2...W]Q]^_%_O7K^ MXM7^ZJBFY/Q2ND*/%YCJ[8?SZ^86^V.9ZF3Q^K=T%>Q]*V?&RE&B0'$"L1OI M1!<+849.V9F*23!R" W.UHFY+J9!3 JK9(';?*F2HFX'HQM26)"8^9,C"L.6 MMZ\OZ8/.\'[$Q'\./%?_&@*S+BX/*BQW"\#5(AV9!.*4ZC@VQ7[K).C_/R8Z M^X+'.OT?Y;G#G!]FA>X796JLD!$L%0G27+J6,,DD$<74*B743"8E25ZWTY:P MH].K'H9&21F3&3*9$E,E9Z!*Y%;U*]$[/'K7+S.K7&XR1V8QS"+F4X/UIUK1 MDE)$)LT352@1AJJ'E4C_WZ>D\7YF#UY$9[&B6?I_7!;^J/7P6_OT)[9[^N8( M)R"SQ6/K?BW-OA-1:2T=% [$E)9";?T3\54X09][^D-"1J&3RL2[39'\&>8.$+:V:S#;( M4FL$9MC[+E /(IZV!.@>#O4.0'#OPM->9^D^#M_0LS\;>],3P]SJ1.R][!&[ MG[(_[_?%)F32ZW9.LVC0PDA/SJ6+Y:^OV25L]4C[ DKHNT).%"LC1$'$'C/P M,5J9N;&QJ61P4_ 2&AO"-3Y15GA&%SCBB"")Y4.S)#6Q=@JHA*@I3"P7N./Q M4BSR"B_E2[Q$,E=]M$SD%(NY/K(R5R$S6 M3TL7):0,,\G2.TID'(-+GEG=SA-VVEL#.K\ES3$A1]@/?"F([[)84H^3RPR. MB#3/2M#,3Z0F,S699-DG*L.W!)9YKLBP,X0@':;S<5,SYU\KK]#MU&X!*M78 M@\<4U18]F4S=7&/6D1)C<**TF"PN+1V!!"EQ6 K'#'T1D %'QX9=L!E((?S8 MO_AH36(F3/[0.1-Y:P&>##\.M[R0 V*7N/U>*;8K(T6?4Y6PPSJ:XMF)"1"[ MK1TP2N\A@.\*HKDW [ >?=1&H-+A!UXEB4D/<+Z.U-*DVA&O*Z5T MY60"]6@ RE22TSER22&1JC#@0![ !G?88 @0O ]F<0H %60#V M+DNMRMFY]!Y;)DHXJ6-L#Y)P-356]<3[P?$ GXHT)$$4I2TGZ")C#>E*4\:)A&8P= MB!:C6!5(F\2X0NMD[1IPG:;QKC !K@*SH/=D->0Z(NM!/4JP&HB,-8D?2,NJ)E.E: M:F>2FP(3:Y)-&"I:O7)1P%)PJK0^'Q(IA(9P:M?0"I5!>!,:W3:_7I$B2+/. MP$:R@?"CI7@"3+355I;O93$E> 4:I=5P>5YC-LH^=N"/C,\3""2X M$:"="K*WXFO=,F6Q%CUT.QP"X /900/ L$^DDFJBD+UWY6/E8S*0NW#D8@G M 'Y;#6BX&0P&YCH5&=R>RF3LP2;8N8#6?UT: #P'E]-(,9%M(QGW7NC!\F K M!#2A[^$_J9][3_W4YOW3,*Z@@)V@+$7L9-M$0LC=A>B]\$&]1ZML:$B!,A.& MDLMEB&]N=81?0=!<02VKA,! #,'<6YV6:6-1?I;( MB$383#@2"J&.:%)N>[ M#0-K52IUMD3G( ?6+X&;A"-=P/["EU>8,J!QJ# YP"2$F[CQS M[!YLTP^_"@'QTK'^NQ(D_UJ2':_L$+CB':!83R9\CG#4(AY2,>VOGSSUYE!: M+^3R-_UKY37^T9[[TA[(3"I_,99SI6,((24E2&%B[(<$=.8]$J2]VWE'08X3 MWNGO 8E9XQQGPAH:Y56G1J=]&&"Y/F./ 9NC8,>CD77PB#&L9)!:2*KR7K%8 MY%YFJR088[T10*'R29(T+3-3 0I2K%X E92&PU)C7)R4 ,53)6,93?';&"19 M/RR:PLT&)4L1CQ'L0; H*%HC%^(6:8[3#^H?KG8[)1Q[%@&25N/&EI6L>0GA M9U3 Q^ML>U1:0D><'*R2>@H3+_@BT5$%OBZ7+AV(]T1*=4U;G%;()U'F*:'T MH#,4"\HQ19 RAIW1KK AGV0Y7XEMSL44@,RC8_X:R\5?7.U_W[]_C,1#&(DA MR"Q\5B@C15SB5%("#[]K_]GML"8W$]_>Z:ZA6PYN82:@@]YY\;@^U WW%8%M M&2V"C2!+,@ "QQBR-'?,V&OFV+N=STJR?RK!CE#A*M5$K\6%X@W]S$)VT.J MLHA^/VC\P?'ICQ4A34W:W=N@2L_IVLA8F,#ZVF$BHQNQ.W@&FF (=0P2+MHS M5CH(R@ZVL=Z&I4>0D9O^2 $F@;Z**9\3? M_YH9#0\ M$J&(H8F6TY %0.@\AMF#*-]?FO1//;^+8 B]'?=-$JTHA U9KK(^#E$!>:WD M9,23)>]._N=BJY&C";&5GZ>1?J]CMF!:OZE,*RVWN],DX/M3Q9UD;^VP5_'R?D$P\;VE0O*/7W,8VS[2Z4[[G'/=ZQPR.4E MPQ+I:B7NU44]2)Q/^E9%U66$&S=XTVP7VEBBXFS<'::D3N8MR[-48PK%M]'V M7D-5@GXLM8#2FYO4 %)?YC3[+KZLH1I/2;5"50QVK3JS5UZQ]V(#S'KR.$]* MEV;[XEIN7^]N!;TY7R8+P02Z0A-:3:8M]I4'KC=0\L*J2&F/:QKTXQEF(+0X M41(1RMXW@M&;@\75Q%G#!,1:3C+CM&ON)%2UP9*-.WGQ;&4G&RO;JUL;-*OF M*Q/7)[O7KS8:GJHIC8NLQ3X-&NTA21KR<*<=QM@4LA8UNO7VNKT+3"3NDD6;<6EV0!^ MFH:PP0B:N>=#'J*W=M!!A:'>*9%L1K\08INU2>%0B%0YI%:]NLFQXJ+= M2KF/P[0Z1>]PR.Z.@E^K*R%D@S#QQ/C05+D"(%.[J:^K@PDFQ4G%52*6+948 MEU1_KVU0NQ;SM:E_Q:V_F?O_Q"I+)?7EW@U=*%7_">E=T^W?[>I9Q/'E[+WO MU0GXM>#T^DBI3$!5,W(CEU2+NT D("$O$572N6D'T(L$UZOF:,'+?!S <;\U MQK>0'-N2^I";>;F!:)4N JF4H:QB$B=3RLYR,,4[&\GLA@BE,@>GD:#8,28$ M0BZZG8DU0!%#<84=YH6)3!25\,0+0\,IV2H^_-#_YBGCE9$U,EY-EF+K.(,; MQ=E:)RYTI+&B3KB@\-BJR;[P505P]GL)7,1;DSGU-?B-07\$RV V$@GO)&%8+.AK;N><*IQ&2F*@@MK*(0+ M$TFXH5@-L,,2-_*IIIP_=51%BX+<"G<$+-)\ZB^ J+%.2.B](Y"CC'KDDD 1 MC9Y)P$7(*L:;&YVI5M"GJ0\E4>4-%<=.SPAOX_,Y?[[DS]T=_V.OYP^/[D^?[N%$X!+92X %UI6 0AQBW>,(5=8 MDHT3FI\K=)3*9 O U3U%0Q8^(]K>\E$BB3\.9!)LWA4W:^M%Q M<\T&>:)%F;],>7K?)5*-=]7B8U-FR_*Y=JY4P1Y1W^4SIOO@1&)MN M?ZFL^N\%=]E]-*-+(.I*=UT7(,S52D)]Z(2!7)D]4E2O8 M_"Y C9(;G9*V&$,E3=70 +Q%+?T)F4R8?00J::_9_;XY1FIWZH=&\48$LBE4 M^IS^_!KZ8;$(7$S"[JD[F;<'U3N:&F[G.)HFQNI8;202X-'E-##7,5=A/'Z$ M7X1M4G4\5WNUF!I.8Z8TH]>P+-L;3)0!HVH?;KVE^,9P0TE-5D_,M--!=.?S M^4HYZ6\FJ:R+ERK4IU[?]SNL#V)4'KW9'8@?* WC(BH-ZFRJ=-&CR(124)S; M>Z=P7( 7^%&]Y^&3/"Y7D1YKBG^R,AUQU\07S]UK=4 M]\\,A443C\=(^-V7L>O4F;-6 Y; ML;>HM+X[\TQ7QD1)P;KK%2KUV-. M+ZV/)Y.9*CTE%0 MYX1WR9-6IY1*6MX?12< MXK_E9"=?#D=&J*1.XE/GA@ZSKKQE4;VAM(&]G)2J]06NQ)O+8:\P^LUEK9$QX-9UVXD5%1"K]^4YG/V/3VA M:^ASQ<'G QMR1JW/OY::7LT<:WJ9R"TK3&^/A[Y$P(H!P2D3SO@![U+;+Y;8 MK]X\" GTAB':%]%49A/.@_J\JZ%WU/P+O9#\V$6(D%JC5MD2- V(.FPX53:B M.AMK#JSMZ@-5HAR':49\BJXD2>8^G['.JO@DO)].NKER7]'\]PZ .] MA+!/G0%A!A)W>,XI-W?-Y<*;SZQF;# F,JN+\?L^(93FTKODP+*9H=JF_Z,= MF9^2.4(6H,E.:KP MU0M^V&W)N_E,L-2<0F M!*)'3FZ]6%$?2ZK9?U*",$D^I<>_!?, NN4-SBBAYMP*@Y$!I'/SM3-<6?CN MX)1JW%R/P)=1U< #1 K5H>6JG4*7G"M3G^'R?*G 35B%31HMLX1OS.Q"WBC* M'$+4DPKSD5QR\Y.@YIV[]TIM+HHEE-Y&"':WMG5<1\]]\ L@W0H;N2DN\B[5 M)S37,01-/-?4,*QN(X6)I%M:&1CI1,[O,RQYJ/@,\U9M4$[E,M[G&=3:^ WN/T@?[!!T_X?[>2$_>XSO-OGO=?[K[H M[[U\^ORO?*S_]PG_<$[ZZ7U*YX9T_V69J'Z5&KXK@W\'=?LBO!7"+[&TGF[^ M=:-&II]GVY#FKQA,J>OPV4Q=MXA\F#/=IC_6Y_]Z'_V1O_\%4$L#!!0 ( M %%!G%813)RA*@, *X+ 1 =&%R82TR,#(S,#0R."YX3G70L!\'A#6JUD/;?NL?5ZO6^CTY--'I+_J9]M& MEP1H4$$7W+?KK,N/T0\\@ JZ @8"*RZ.T2.FD;'P2T)!H',^""DHT(XD4@45 M0?<16,#%0ZL^U>TK%NP_8?A^X]^5?X?%";S2;\.KX.@: MLS8F>!S?E9KM?#U_=I]%]\RH)695^'P88Z M\]QLM&.?Z1; 0"6I6LC0R6C06"J!+&(FCI6/C M(=L,261*T\N84G66P7,2D83@EIW$ZU" U+PX_88VI,04LH'D8^I'=#_.+)6U ME-20'=/LX++1:$$7Q2-5,9=?LR0QCYJ5VOH"NC7+'*2=W<]/75I.-T<&,=); M1BH^^>732 -G$ECX*RHK(V]N- 2AB.[0N;E.4B?*T._FPB 31UK(^1WF[X.7&,IAEND\2LQ/8+XF,=T 2&Y[E=?'E)KA9Q"VT:] -S_O6H&LY M#E E,\O!*YO3>8\9[^5!3>#SB"DQ MV:<1YBG9YK#;F/W&=[N(#)]<@OFS'QKV@"Y8#;ZN!:I.HJ:7?P!02P,$% M @ 44&<5BT:84O^"@ @(8 !4 !T87)A+3(P,C,P-#(X7VQA8BYX;6S- MG5UOX[@5AN\+]#^P[DT+C.-Q@BV:[&07&4^R,#:;I+%GMNVB6- 2XPBAR8"2 M$_O?EY1$6:)X)"5%2<[%C$=\#_52?$Q27\>??MQM*'HA(DTX.Q]-CSZ.$&$1 MCQ.V/A]]78PO%K/Y?(32#+,84\[(^8CQT8\__/$/2/[Y]*?Q&%TEA,9GZ N/ MQG/VP+]'-WA#SM!/A!&!,RZ^1]\PW:HM_"JA1* 9WSQ3DA%94.SX#'UW-/T[ M1N/Q@'J_$19S\?5^7M7[F&7/Z=ED\OKZ>L3X"W[EXBD]BOAF6(6+#&?;M*KM MX^YC^:<(_T03]G2F_EKAE"!YO%AZMDN3\Y':;[G;UY,C+M:3XX\?IY-__G*] MB![)!H\3IHY;1$8Z2M5BBYN>GIY.\E(M;2EW*T'U/DXFVDY5LRQ-.O0U)VER MEN;VKGF$L[S;>W>#0(7ZWUC+QFK3>'H\/ID>[=)XI ]^?@0%I^2>/*"\F6?9 M_EFBE":*A%&Y[5&0![L9*L1$Q4\86>.,Q&I'IVI'T[^I'?VYW'R-5X2.D%)* M/L!VG3;J*H,FKLW>$9'P^)*]S[49[>1.6/,/T7>;KD8;/5]31,6 FUC, DUK:>!_9ZL$S6U* OJ_):HC1W# M&*!W/?1WVC;G JLX"&B&. 1GBWH0JJ(\<73!V!;3>_+,11<^39EK:FPF35CJ MFJ 8L1@#T2BTJ!![(N(?6WG&3@3=]T+14KKF K!JHF'(@J+#[@T$I)+[960I M,$L3-8#U0M*6.C_= ,RV3CT,75"< .;@4Y)*[Y>4Q2.A5-T/P*Q_0+&)7=," M&S9Y:2N#(@:T!S*31Z R)!QL+E_4ZEPNDP8VMJ;W"4_+=A<_E3A8A$R' RG* MPY"*\T12[39$#T,MI6MZ *LF-X8L*&+LWD!6"CG*]?XAN63Q($0JG1] #)MV M/$I1@' TG?6A(=4^P;A*T@C3PLN5W)9V-,^B=0T(:->$I"4,"A3('0A+$:"9 MR4.\ O,O@L4P7&I*/["TK-I1J60!@F)ZZ\-$Z;U ,ML*T7 -SSBPU-E-V1ZS MU?U90!<$*#WF6G=M"WD#%$\ST"7+DFROGJ>[V6Y61%@:UY:X8@,RIYDPRX-@ M 3!E,E#(D-*A0NBEY_5= I:IAQC!YI@RMP38338I:&H"(L%J#*#AH,V?*?5" MQ$R.3 +3.8O)[F>R!]O5TKEE K#9A,(0!42%W1F 12E&N1I)N1J:(M=(L&9+3)AJD*" [ &D!'J4:+^DN)Y\!Y*0+U; M6'IL-YD!Q &AT^T0($@&H6:43Y#F+.+BF=<>=YCQK1P ]S,>PRN4GBBW4 UJ M0A.MSI" !OB$\"L$?JA>"8%3UX!4C5X(>XBCN6!2LM_KA-&IF#[K5JW M='78;3)E$09$$NP.X*=4?M ?D(I!MRP4:([?T-1C_] <#X7F.&AHCM\#S?*5 M!P+-R1N:>N(?FI.AT)P$#]UK)G)C[=BR5]M#V>#2B_(M*U:@3G( MPL.EY:T/%A6@UC,JQ"%R'4W*T8%P<"(T"QVULD64U4?U\K"Z.*VH58/Y]]KJ?'Q15;9 M7>C=(V?P P)MB:N>ALSIWC;+@^AQP)39Z[D,Y3I/5^-5AHG4/GS7RIS-[*:= M:B+7!4'TKNFF-4WK]^:M(,KGG&=]LMJR\RV-[;A#0N>KE3INZQZVB('J_ MRYE)0JE%3;%C+!:<)E&2)6S]BSSY% FVM5!L &8,EG(RQ!_0-/COZS^BG24X^Z_X4N!5?+8Q7ZS MXA3(/F55N8*@PZ+FP"() @78ETG##4>E%!5:']FI&F8MS3'*70%@M:6[OE$8 M1*?;'+6^_(V^]C3D7^ZB1VF* "\DV&6NAWZ;27/XKVN"0*##6.NDI)0BK?7Q M0L)AREKW+P+6WA8!ZYY%P#K$1 AU:7K2^G% QB_$DI_9OR5+0A..2-Q<2W%=J>H M6^_VB9D>V\V'9@!Q$#@-<0@\.J."QD\J"NFP\DJ8%Y*^<;IE&1;YN^3"-C(! M.K?D #:;Q!BB@$BQ.P,(J<2H4/MY0;O('E$MLHK?'0(;",D=OZ[=:=IX:]NJ M#8B93H/0.]QESH_#VKB(\O2*94;4[T4D+^0+SG#I#6PO)'?]4F67:?-M2ILV M((0Z#8+O3U8Q*E4,UDQY2QDC9G*IM>8=3XD;*O>)8UH6V[EC*DE >-A\=620 M$4AKO;"PV&!*/V_3A)$4GH@,E5L6K!:;+#0D ;%@\P6PD$N1UGIAX7)#Q%I. M;S\)_IH]EOE9P;8!:K=L=%IN,F*5!L1*ES^ &1V"BAB=4MH25'7U."LD>"+LN?H:MG@B_J\?5+ M(U&D7H@H5N4LQL*&4)?8^:^.@(9;OSW24@8!4J\]^'=(J@BD0QQ3SL_20Q9 $G_>WY,'(M1[ M!TNRRS[+'3UUG&$,B'5]]C:X.>;)7&]@$!"^U2UTJI>B>@5HI9X1*ZM OZE* M4%Z+[??+ZYNNY2>Y66^2?ZUP2N26_P)02P,$% @ 44&<5I%$T?]6!P MUU< !4 !T87)A+3(P,C,P-#(X7W!R92YX;6S-G%U3VS@4AN]W9O^#-WL= M0D*[6RAL!U+2R90"2VB[NS<=Q582#;*4D622_/N5[#C-AR4?;GS@ H+SZN-] MCBW[V)+//RQ3'CU3I9D4%ZWNT7$KHB*6"1/3B];74?MRU!\.6Y$V1"2$2T$O M6D*V/OSUZR^1_3G_K=V.!HSRY"SZ*./V4$SD^^B6I/0L^D0%5<1(]3[Z1GCF MML@!XU1%?9G..374?E$T?!:]/>J^(U&[#:CW&Q6)5%\?AIMZ9\;,]5FGLU@L MCH1\)@NIGO11+%-8A2-#3*8WM1TOC]<_1?%SSL33F?LU)II&EI?09TO-+EJN MW76SBY,CJ::=WO%QM_//EYM1/*,I:3/AN,6T599RM525ZYZ>GG;R;TOI@7(Y M5KQLXZ13=F=3L_V6!?1;/='L3.?=NY$Q,7G8:YN)O KW7[N4M=VF=K?7/ND> M+772*N'G!)7D](%.(O?71F_3ZEQ)0^R.LG01Z[AO.WUI]TC;U;S<3-')1N\M]W1&8UMWNF9F[':D6=G8;GBFHJ3.[UQF[8*4*7QNY/-"DK MKU[M*-VF[?RE+;F/U8*-<]*?O"9;S3/'R_TY)ZUI?#25 MSYV$LH[S[S[D('((]I\?>4.78VT4B4U9$R=CRO/Z?UC-GJ330*]*$H^VQNI. M[2KV^[0=M4L51U(E5%G695U$Q3NQ.MPUUXK.G"A;43N>,;X)\T3)U$=G34)Z M.KH-RC;1#,U+VW[B^C#@9%J-:.2PW8'260;P^5 M;X6WAC&7Q\X#G3+77]<5=\*E;F-X7/ 4 8(_P1PI@FZ1(G I1$;X YU+50-^ M5PGD_0:3=Y4W),Q_9T09JO@*0OI #(3]%A.VQR$2[T=%A&:.#P3XH1I(_ _4 M"P^/1R3DHQGEW"5Q1(#V\BH]$/N?F-C]/E\!^.MG=WZWIQ8X^ZTB0/SO7@O^ M [=($;BGBLG$GM(5@/V!&$C]%).ZQR$J[VN10&EOI.#\!Q_VGCTDU .F8\*+ M'@WL-AW&72&'(D?).6MMHF+_EQ(%AKXEAB)'24-K+#8,O)\IM=.9X*CB5T.1 MHR2@=28;9GXM##,K=]?_-DO'/V^<[K(^5$$9HR2=/E,H;,L[#<*XAQDAOOM* M*&.47#-D#H5SW_I1A ]%0I>?Z2H$^D *)8V28P;MH:"^5RPE:C5BXM V:.DE2"[*"$8BEBJN=RZ7=R7F3T> M5WV9!(?TFH+0<*#DFR^PCA*4RR2QN/3ZSPT3M!L*1:4<_(P(+P !FZ\$>^]E MV'MP["AY:*W-5X+]Y&783^#847+16IN8V/OVXYUZE O/$VBO&(H<)1>ML8@) M/#_3W*E[)9]9,2NJCOI!"2AZQ!0U;!9UAR].\I"]O51">2.FJ]7F,#G?2VT( M_X_-ZZXDJ_50YHB):\AHTS<8B[B[FQ:^J41[$BA?E%RUTD[32%V$%27^W7=7 M 06*DH!6F6F8YXUTSSYF4@3OQQZJH%Q1,DF?J:8'7C>36'L/_:VOP3/84(;5 M?1L-8_RNF+$]Z,LTS<3Z'HWGJ9A'"L6+DOX%[36,>B0YBYEA8OK%7B$J1G@U MYRH=%#)*LNT5=I*F][,[G<;FE!NIN,O&-O"$]E#A*KE=O%)?\4.N, MJI?RKR@%C0)*V@$:9 Q64-4K*YS/5,-M;^:B( M6ZTW6J5CR?W+0RJ%4,(H"5[ 6L.0=_I1C7=/ @6+DME5VD$:$ZZ7\8R(*?7/ M7JA60@&C9'HAOY( M8;-(\],,=7UFS_0C,63=PQ!_7PDH?\0'BF&S://G5=^>>*8R_,Q\3PBEC3@5 MMM(:"N112CB_RC035 ?'ECTA%#+BG-=*:RB0KU.JIG90^Z3DPLS6:SM#L#T% MH- 19[8&K>+ 7_Y<1UZL?PN2KU"#WTZ B-UK$NNU&W'L)E(49W*1$.6A'M)# MN:,NK/0;;9C\G9E1M7W]E'=F:/.VT*2'^E+0**"DJU#3..?6K97\P5/KC@[* M&S$QK3*&LV8J&W,6#[@DP>OR'1F4+V(66F$+!>\5$4\JFYMX=:]D3*E[?*(W M1QL@(0)6 T)8G[Z(A0XMPMDFKK%1#)^&LVL:7V7F?S]I;9_P9L&P7+0T& N MX@081[H*TC\7>M'D:O5 )U2Y:0J/=&FN;$-/X8LB0'%H?%#?* 3&4!&F\\Z! MKQN[P;VAMOC&_7)O8;5;_@=02P$"% ,4 " !109Q67@4AFE02 #!; M%P @ $ 96$Q-S#DY+3%?<')O=&%R82YH=&U02P$"% ,4 " !109Q6$4R&UL4$L! A0#% @ 44&<5I%$T?]6!P UU< M !4 ( !X34 '1A